FDA approves innovative drug for menopausal hot flashes.

TL;DR Summary
The FDA has approved Veozah, an oral medication that targets the neural activity causing hot flashes during menopause. It is the first neurokinin 3 receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause. Veozah is not a hormone and is an additional safe and effective treatment option for women who cannot take hormone therapies. The most common side effects of Veozah include abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases.
- FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause FDA.gov
- FDA green lights a new type of drug for menopausal hot flashes CNN
- F.D.A. Approves New Drug to Treat Hot Flashes The New York Times
- New menopause drug for hot flashes gets FDA approval The Associated Press
- US FDA approves Astellas Pharma pill for menopause hot flashes Reuters
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
87%
617 → 80 words
Want the full story? Read the original article
Read on FDA.gov